The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial.
 
Thomas Aparicio
Honoraria - Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Ipsen; Novartis; Roche/Genentech; Sanofi
 
Olivier Bouche
Honoraria - Novartis
Consulting or Advisory Role - Merck Serono; Roche Pharma AG
 
Eric Francois
Honoraria - Roche Pharma AG
 
Emilie Maillard
No Relationships to Disclose
 
Sylvie Kirscher
No Relationships to Disclose
 
Julien Taïeb
Honoraria - Roche Pharma AG
 
Pierre-Luc Etienne
No Relationships to Disclose
 
Roger Faroux
No Relationships to Disclose
 
Faiza Khemissa
No Relationships to Disclose
 
Farid El Hajbi
No Relationships to Disclose
 
Christophe Locher
Honoraria - Merck Serono; Novartis; Roche Pharma AG; Sanofi
 
Yves Rinaldi
No Relationships to Disclose
 
Thierry Lecomte
No Relationships to Disclose
 
Sandrine Lavau-Denes
Consulting or Advisory Role - Bristol-Myers Squibb (I); Sanofi
Travel, Accommodations, Expenses - AstraZeneca
 
Mathieu Baconnier
No Relationships to Disclose
 
Alice Oden-Gangloff
No Relationships to Disclose
 
Dominique Genet
No Relationships to Disclose
 
Elena Paillaud
No Relationships to Disclose
 
Frederic Retornaz
No Relationships to Disclose
 
Laurent Bedenne
Research Funding - Merck Serono (Inst); Roche Pharma AG (Inst)